Literature DB >> 20172036

Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.

James T Milnes1, Harry J Witchel, Joanne L Leaney, Derek J Leishman, Jules C Hancox.   

Abstract

INTRODUCTION: Pharmacological inhibition of cardiac potassium channels encoded by hERG (human ether-à-go-go-related gene) is associated with QT interval prolongation and torsades de pointes arrhythmia. Electrophysiological assays of hERG channel inhibition are integral to the safety testing of novel drug candidates. This study was conducted to compare, for the high affinity hERG inhibitors dofetilide and cisapride, hERG blockade between action potential (AP) and conventional (step and step-ramp) screening waveforms. Furthermore, it evaluated dynamic (pulse-by-pulse) protocol-dependence of hERG channel inhibition by these drugs.
METHODS: Whole-cell patch-clamp recordings were made at 37 degrees C from hERG-expressing HEK 293 cells. Half-maximal inhibitory concentrations (IC(50) values) for I(hERG) blockade were obtained using conventional voltage clamp and action potential clamp, using previously digitised ventricular and Purkinje fibre (PF) AP waveforms.
RESULTS: A more marked variation in IC(50) values with different command waveforms was observed for cisapride (ranging from 7 to 72 nM) than for dofetilide (ranging from 4 to 15 nM), with higher IC(50)s obtained with AP than step or step-ramp commands. The two drugs differed little from one another in effects on voltage-dependent activation; however, I(hERG) blockade by each drug was initially voltage-dependent, but at steady-state was only voltage-dependent for cisapride. There was comparatively little difference between the two drugs in effects on I(hERG) availability or time constants of development of inactivation. Features of time-dependence of blockade and the use of protocols employing varying rest periods in drug or commands of alternating duration highlighted a pronounced ability of cisapride, but not dofetilide, to dissociate and reassociate from hERG on a pulse-by-pulse basis. DISCUSSION: Protocols described here that demonstrated dynamic variation (drug dissociation/reassociation) in hERG channel current blockade at 37 degrees C for cisapride may have future value for investigating drug interactions with the hERG channel. Downloadable digitised ventricular and PF AP waveforms that can be used in AP clamp experiments also accompany this article. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20172036     DOI: 10.1016/j.vascn.2010.02.007

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  26 in total

1.  Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers.

Authors:  Corina Loghin; Harry Haber; Charles M Beasley; Prajakti A Kothare; Lynnette Kauffman; John April; Ling Jin; Albert J Allen; Malcolm I Mitchell
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 2.  Evolution of strategies to improve preclinical cardiac safety testing.

Authors:  Gary Gintant; Philip T Sager; Norman Stockbridge
Journal:  Nat Rev Drug Discov       Date:  2016-02-19       Impact factor: 84.694

Review 3.  Mechanobiology Assays with Applications in Cardiomyocyte Biology and Cardiotoxicity.

Authors:  Cheavar A Blair; Beth L Pruitt
Journal:  Adv Healthc Mater       Date:  2020-04-09       Impact factor: 9.933

4.  A temperature-dependent in silico model of the human ether-à-go-go-related (hERG) gene channel.

Authors:  Zhihua Li; Sara Dutta; Jiansong Sheng; Phu N Tran; Wendy Wu; Thomas Colatsky
Journal:  J Pharmacol Toxicol Methods       Date:  2016-05-11       Impact factor: 1.950

5.  Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting.

Authors:  Xi-Ping Huang; Thomas Mangano; Sandy Hufeisen; Vincent Setola; Bryan L Roth
Journal:  Assay Drug Dev Technol       Date:  2010-12       Impact factor: 1.738

6.  Allocryptopine and benzyltetrahydropalmatine block hERG potassium channels expressed in HEK293 cells.

Authors:  Kun Lin; Yu-qi Liu; Bin Xu; Jin-liao Gao; Yi-cheng Fu; Yu Chen; Qiao Xue; Yang Li
Journal:  Acta Pharmacol Sin       Date:  2013-03-25       Impact factor: 6.150

7.  Class 3 inhibition of hERG K+ channel by caffeic acid phenethyl ester (CAPE) and curcumin.

Authors:  Seong Woo Choi; Kyung Su Kim; Dong Hoon Shin; Hae Young Yoo; Han Choe; Tae Hee Ko; Jae Boum Youm; Woo Kyung Kim; Yin Hua Zhang; Sung Joon Kim
Journal:  Pflugers Arch       Date:  2013-02-26       Impact factor: 3.657

8.  Identifying the translational gap in the evaluation of drug-induced QTc interval prolongation.

Authors:  Anne S Y Chain; Vincent F S Dubois; Meindert Danhof; Miriam C J M Sturkenboom; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

9.  In silico Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel-A Drug Antitarget.

Authors:  Ehab Al-Moubarak; Mohsen Sharifi; Jules C Hancox
Journal:  Front Cardiovasc Med       Date:  2021-05-04

10.  Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel.

Authors:  Aziza El Harchi; Dario Melgari; Yi Hong Zhang; Henggui Zhang; Jules C Hancox
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.